Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Financial Statements Details - Intangible Assets, Net - General Information (Details)

v3.26.1
Condensed Consolidated Financial Statements Details - Intangible Assets, Net - General Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Intangible assets, net    
Cost $ 47,923 $ 47,923
Accumulated Amortization 4,059 3,167
Net Carrying Value $ 43,864 44,756
Minimum    
Intangible assets, net    
Estimated remaining life of intangible assets 10 years 8 months 12 days  
Maximum    
Intangible assets, net    
Estimated remaining life of intangible assets 19 years 8 months 12 days  
Pulmokine - Seralutinib IP    
Intangible assets, net    
Cost $ 26,115 26,115
Accumulated Amortization 2,926 2,383
Net Carrying Value 23,189 23,732
BioInvent - Contract-based Intangible Asset    
Intangible assets, net    
Cost 20,725 20,725
Accumulated Amortization 1,115 780
Net Carrying Value 19,610 19,945
LAVA - Partnered Program IPs    
Intangible assets, net    
Cost 934 934
Accumulated Amortization 16 3
Net Carrying Value 918 931
LAVA-1266 IP    
Intangible assets, net    
Cost 149 149
Accumulated Amortization 2 1
Net Carrying Value $ 147 $ 148